Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.16 USD | -0.92% | -4.00% | +23.43% |
05-13 | Transcript : Stereotaxis, Inc., Q1 2024 Earnings Call, May 13, 2024 | |
05-13 | Stereotaxis to Buy Access Point Technologies | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+23.43% | 177M | C+ | ||
+11.29% | 225B | B | ||
+8.76% | 186B | B- | ||
+12.90% | 135B | B- | ||
+25.95% | 107B | A- | ||
+0.49% | 63.56B | A- | ||
+5.62% | 51.32B | B+ | ||
+11.08% | 51.04B | B+ | ||
+6.28% | 43.3B | A | ||
+4.80% | 36.99B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- STXS Stock
- Ratings Stereotaxis, Inc.